- "We believe the company will abandon attempts to gain approval for the indication meaning that Vascepa will only be approved for what appears to be a niche indication," says analyst William Tanner, reiterating his Market Perform rating and $2 price target on Amarin (AMRN -24.9%) following the FDA declining the reinstate the ANCHOR SPA.
- Investors, he says, face significant dilution even if Amarin discontinues the REDUCE-IT trial. With $226M ($1.30 per share) in cash at the end of Q3 and an $80M/quarter burn rate this year ($30M-$40M for REDUCE-IT), the company has about two years of liquidity. "We doubt the company could achieve break-even status with just the MARINE indication."
From other sites
at Zacks.com (Apr 9, 2015)
at Zacks.com (Feb 25, 2015)
at Zacks.com (Feb 23, 2015)
at Benzinga.com (Jan 13, 2015)
at CNBC.com (Feb 28, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs